- Open
- 195.00
- High
- 196.72
- Low
- 195.00
- Close
- 195.00
- Change
- +0.00 (0.00%)
- Volume
- 25,951
⌘K
| 30 Apr 2026 | 09:30:00 | Total Voting Rights |
| 29 Apr 2026 | 11:00:00 | HUTCHMED Announces NDA Acceptance in China |
| 9 Apr 2026 | 09:30:00 | 2025 Annual Report and Notice of AGM |
| 9 Apr 2026 | 07:00:07 | Data to be Presented at AACR Annual Meeting 2026 |
HUTCHMED is a biopharmaceutical company that focuses on developing targeted therapies and immunotherapies for cancer and immunological diseases on a global scale. They are dedicated to innovation and commercialization in the field of biopharmaceuticals.
| 30 Apr 2026 | 09:30:00 | Total Voting Rights |
| 29 Apr 2026 | 11:00:00 | HUTCHMED Announces NDA Acceptance in China |
| 9 Apr 2026 | 09:30:00 | 2025 Annual Report and Notice of AGM |
| 9 Apr 2026 | 07:00:07 | Data to be Presented at AACR Annual Meeting 2026 |
HUTCHMED is a biopharmaceutical company that focuses on developing targeted therapies and immunotherapies for cancer and immunological diseases on a global scale. They are dedicated to innovation and commercialization in the field of biopharmaceuticals.
| 23 Mar 2026 | 07:00:13 | HUTCHMED Initiates Phase III Trial of HMPL-760 |
| 23 Mar 2026 | 07:00:13 | HUTCHMED Initiates Phase III Trial of HMPL-760 |